跳至主要内容
临床试验/NCT02610452
NCT02610452已完成不适用

Assessing the Impact of Clown Therapy in a Palliative Care Unit: A Prospective, Descriptive Study

Centre Hospitalier Universitaire de Nīmes1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2016年3月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
30
试验地点
1
主要终点
ESAS questionnaire

研究概览

简要总结

The main objective of this study was to assess changes in the quality of life of patients in a Palliative Care Unit via the symptoms by the Edmonton Symptom Assessment System (ESAS) before and one hour after the passage of a clown therapist .

详细描述

The secondary objectives of this study are to evaluate before versus after the intervention of clowns therapists:

A. Changes in the quality of life at two days after the intervention (using the ESAS).

B. The quality of life two days after the intervention via the McGill Quality of Life Questionnaire.

C. The quality of life of patients after the intervention as assessed by semi-structured interviews conducted by the department psychologist.

D. The quality of life of caregivers after the intervention as assessed by semi-structured interviews conducted by the department psychologist.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •The patient must have given his/her informed and signed consent
  • •The patient must be insured or beneficiary of a health insurance plan
  • •Patient receiving palliative care, ie with a severe and progressive disease bringing into play vital prognosis, in advanced or terminal phase
  • •Clinically stable patients, regardless of disease type. The existence of clinical symptoms (pain, discomfort, etc.) found at recruitment by the investigator and not affecting the mental clarity of the subject, does not justify the exclusion of the patient
  • •Absence of cognitive disorders; since the protocol provides a clinical interview covering in particular his/her quality of life, included patients will be able to express their feelings
  • •In addition, patients who have undergone this type of intervention (clown therapist) will not be excluded from this study.

排除标准

  • •The patient is participating in another study
  • •The patient is an adult under judicial protection
  • •The patient refuses to sign the consent
  • •It is impossible to correctly inform the patient
  • •Patient with an inability to fill our protocol assessment scales
  • •Patients under treatment known to reduce the level of awareness
  • •Patients with major cognitive impairment
  • •Patients with symptoms that bring into question their level of awareness
  • •Patients with significant risk factors and who should benefit from personalized monitoring from the team (clinically unstable patients, emergency situations, agitated patients, dementia, etc ...).
  • •Patient is unable to submit to the continuity of the study.

研究组 & 干预措施

The study population

Experimental

The study population consists of adult patients treated in the Palliative Care Unit of the University Hospital of Nimes, regardless of their original condition. In 2013 the proportion of stays connected with diagnostics for cancer was 70.16%.

Intervention: Clown therapy

干预措施: Clown therapy (Other)

结局指标

主要结局

ESAS questionnaire

时间窗: Day 2

The ESAS (Edmonton Symptom Assessment System) self-administered questionnaire

ESAS questionnaire

时间窗: 1 hour before clown therapy session

The ESAS (Edmonton Symptom Assessment System) self-administered questionnaire

ESAS questionnaire

时间窗: 1 hour after clown therapy session

The ESAS (Edmonton Symptom Assessment System) self-administered questionnaire

次要结局

  • Semi-directed caregiver interview(Day 0)
  • McGill Quality of Life Questionnaire(Day 2)
  • Semi-directed patient interview(Day 2)
  • Semi-directed staff interview(Day 0)
  • McGill Quality of Life Questionnaire(1 hour before clown therapy session)

研究者

发起方
Centre Hospitalier Universitaire de Nīmes
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Assessing the Impact of Clown Therapy in a... | 临床试验